Journal of Clinical Investigation - Cardiology

DECEMBER 15, 2023

Heart failure with preserved ejection fraction (HFpEF) is a widespread syndrome with limited therapeutic options and poorly understood immune pathophysiology.

Preserved Ejection Fraction 75

Preserved Ejection Fraction Heart Failure Obesity Ablation 75

American College of Cardiology

NOVEMBER 16, 2024

The goal of the SUMMIT trial was to compare the safety and efficacy of tirzepatide among patients with heart failure with preserved ejection fraction (HFpEF) and obesity.

Preserved Ejection Fraction 49

Preserved Ejection Fraction Heart Failure Obesity Article 49

American College of Cardiology

NOVEMBER 16, 2024

In patients with obesity and heart failure with preserved ejection fraction (HFpEF), weekly treatment with tirzepatide over approximately two years reduced the risk of worsening heart failure events, based on findings from the SUMMIT trial.

Preserved Ejection Fraction 75

Preserved Ejection Fraction Quality of Life Obesity Heart Failure 75

Med Page Today

APRIL 7, 2024

(MedPage Today) -- ATLANTA -- Weight loss and heart failure benefits with semaglutide (Wegovy) extended to patients with obesity-related heart failure with preserved ejection fraction (HFpEF) who have type 2 diabetes, the STEP-HFpEF DM trial showed.

Preserved Ejection Fraction 96

Preserved Ejection Fraction Diabetes Heart Failure Obesity 96

American College of Cardiology

APRIL 10, 2024

What are the effects of semaglutide across a broad range of outcomes in people with obesity-related heart failure with preserved ejection fraction (HFpEF) with and without diabetes, and consistency across key patient subgroups?

Preserved Ejection Fraction 61

Preserved Ejection Fraction Obesity Heart Failure Diabetes 61

American College of Cardiology

JULY 16, 2024

For patients with obesity-related heart failure with preserved ejection fraction (HFpEF), what is the effect of semaglutide on change in New York Heart Association (NYHA) functional class over time?

Preserved Ejection Fraction 61

Preserved Ejection Fraction Obesity Heart Failure Article 61

American College of Cardiology

AUGUST 26, 2024

The goal of the STEP-HFpEF trial was to compare the safety and efficacy of semaglutide among patients with heart failure with preserved ejection fraction (HFpEF) and obesity.

Preserved Ejection Fraction 58

Preserved Ejection Fraction Obesity Heart Failure Article 58

American College of Cardiology

JUNE 24, 2024

Semaglutide reduces body weight to a greater extent in women with obesity-related heart failure with preserved ejection fraction (HFpEF) than in men, and improved Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) to the same extent in both women and men, according to results from a prespecified secondary analysis of pooled (..)

Preserved Ejection Fraction 66

Preserved Ejection Fraction Obesity Heart Failure Cardiomyopathy 66

European Journal of Heart Failure

DECEMBER 7, 2023

Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF). Echocardiography demonstrated increased CO with obesity, but not estimated right atrial (RA) pressure or E/e′.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Obesity Heart Failure BMI 40

American College of Cardiology

SEPTEMBER 26, 2024

Does semaglutide efficacy vary with baseline diuretic use and does semaglutide change diuretic dose in patients with heart failure with preserved ejection fraction (HFpEF)?

Preserved Ejection Fraction 64

Preserved Ejection Fraction Obesity Heart Failure Article 64

HeartRhythm

SEPTEMBER 4, 2024

Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) are comorbid conditions that are increasingly prevalent and have a high socioeconomic burden. This article discusses their shared pathophysiology, focusing on the triad of hypertension, obesity, and aging.We

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Quality of Life 40

American College of Cardiology

JULY 1, 2024

What is the effect of semaglutide compared with placebo on N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels in patients with heart failure and preserved ejection fraction (HFpEF)?

Preserved Ejection Fraction 58

Preserved Ejection Fraction Obesity Heart Failure Article 58

Cardiovascular Diabetology

SEPTEMBER 10, 2024

Although the “obesity paradox” is comprehensively elucidated in heart failure (HF) with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF), the role of body composition in left v.

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Obesity Outcomes 52

Journal of the American Heart Association

FEBRUARY 14, 2024

Pathological increases in renal sympathetic nerve activity contribute to the pathogenesis of heart failure with preserved ejection fraction (HFpEF).We

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Blood Pressure Biomarkers 40

JAMA Cardiology

NOVEMBER 15, 2024

In this case series study, pulmonary artery systolic, diastolic, and mean pressures of 2 participants with obesity and heart failure with preserved ejection fraction were measured at zero gravity during parabolic flight to assess the effect of external constraint on left ventricular filling pressures.

Preserved Ejection Fraction 63

Preserved Ejection Fraction Heart Failure Obesity Pulmonary 63

American College of Cardiology

DECEMBER 13, 2023

Obesity is quite common in patients suffering from heart failure with preserved ejection fraction (HFpEF). Semaglutide is a glucagon-like peptide-1 receptor agonist that has been shown to cause weight loss and reduce cardiovascular events in patients with obesity.

Preserved Ejection Fraction 64

Preserved Ejection Fraction Heart Failure Obesity Article 64

The New England Journal of Medicine

NOVEMBER 15, 2024

In this audio interview, Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research being presented at the 2024 American Heart Association Scientific Sessions.

Preserved Ejection Fraction 45

Preserved Ejection Fraction Heart Failure Obesity Research 45

NEJM Journal Watch - Cardiology

NOVEMBER 25, 2024

Tirzepatide significantly decreased the risk for a composite endpoint of worsening heart failure or cardiovascular death.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Obesity Outcomes 40

DAIC

JULY 31, 2024

mtaschetta-millane Wed, 07/31/2024 - 06:00 July 31, 2024 — A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & Vascular Institute, demonstrates the effectiveness of a newly developed scoring system in identifying patients with Heart Failure with Preserved Ejection Fraction (HFpEF).

Heart Failure 111

Heart Failure Preserved Ejection Fraction Research Hospital 111

Circulation

NOVEMBER 11, 2023

Background:Patients with heart failure (HF) with preserved ejection fraction (HFpEF) and obesity experience high burden of symptoms and functional impairment, and a poor quality of life. Circulation, Ahead of Print. In the STEP-HFpEF trial, once-weekly semaglutide 2.4 across domains;P<0.05

Preserved Ejection Fraction 40

Preserved Ejection Fraction Quality of Life Obesity Heart Failure 40

American College of Cardiology

MAY 20, 2024

The GLP1RA semaglutide reduces N-terminal pro-brain natriuretic peptide (NTproBNP) in patients with obesity-related HF with preserved ejection fraction (HFpEF), and it may hold greater benefits for patients who start treatment with a higher baseline NTproBNP.

Preserved Ejection Fraction 45

Preserved Ejection Fraction Obesity Article 45

Cardiometabolic Health Congress

NOVEMBER 14, 2024

42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. Key Takeaways: Natriuretic Peptides : Useful for diagnosing and monitoring heart failure, particularly HFrEF, but challenging to interpret in patients with obesity due to peptide deficiency. In the U.S.,

CME 103

CME Obesity Heart Failure Biomarkers 103

Circulation

SEPTEMBER 2, 2024

Circulation, Volume 150, Issue 10 , Page e224-e225, September 3, 2024.

Preserved Ejection Fraction 45

Preserved Ejection Fraction Quality of Life Article Heart Failure 45

Clinical Trial Results

NOVEMBER 16, 2024

Disclosures: TBD

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Obesity 40

Circulation: Heart Failure

SEPTEMBER 12, 2023

BACKGROUND:Obesity and adiposity are associated with an increased risk of heart failure with preserved ejection fraction (HFpEF); yet, specific underlying mechanisms remain unclear. Fasting blood samples collected at the time of the cardiopulmonary exercise test were used to assay obesity-related biomarkers.

Biomarkers 40

Biomarkers Obesity Exercise Preserved Ejection Fraction 40

European Journal of Heart Failure

DECEMBER 13, 2023

Association between epicardial adipose tissue (EAT) and cardiac dysfunction in severe obesity. Abstract Aim Epicardial adipose tissue (EAT) plays a role in obesity-related heart failure with preserved ejection fraction. BMI, body mass index; GLS, global longitudinal strain; LASct, left atrial contractile strain.

Obesity 40

Obesity Preserved Ejection Fraction BMI Heart Failure 40

Cardiometabolic Health Congress

JULY 25, 2023

Can you please explain the concept of an obesity paradox? Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. 2, 3] This association is more pronounced for those with class I obesity, which is a body mass index (BMI) between 30-35 kg/m2.

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

Cardiometabolic Health Congress

NOVEMBER 22, 2024

Heart Failure Management : The FINEARTS-HF trial focused on the efficacy of finerenone, an aldosterone antagonist, in reducing heart failure hospitalizations and cardiovascular mortality among patients with preserved ejection fraction (HFpEF). Eckel, MD, FAHA, FACC at the 19th Annual CMHC.

Blood Pressure 59

Blood Pressure Obesity Preserved Ejection Fraction Coronary Artery Disease 59

CardiacWire

AUGUST 2, 2024

Lilly’s blockbuster GLP-1 tirzepatide appears poised to become the next major HFpEF drug, after topline results from the SUMMIT trial showed that it significantly improved both outcomes and symptoms among patients with heart failure with preserved ejection fraction and obesity.

Outcomes 59

Outcomes Preserved Ejection Fraction Heart Failure Obesity 59

Clinical Trial Results

SEPTEMBER 1, 2024

Disclosures: TBD ESC 2024_Rabea_Asleh Download

Preserved Ejection Fraction 40

Preserved Ejection Fraction Download Heart Failure Obesity 40

Circulation

NOVEMBER 11, 2024

Intro:Drug Development for Heart failure with Preserved Ejection Fraction (HFpEF) is a major challenge facing cardiovascular research due to its complex pathophysiology and existence of comorbidities, leading to recognize distinct HFpEF phenogroups. l) for 8 weeks.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Hypertension Blood Pressure Obesity 40

Circulation

NOVEMBER 11, 2024

The CardioMEMS PA (pulmonary artery) sensor allows remote pulmonary artery diastolic (PAD) pressure monitoring to adjust diuresis in heart failure with preserved ejection fraction (HFpEF).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Cardiomyopathy Heart Failure Pulmonary 40

DAIC

FEBRUARY 29, 2024

ET Murphy Ballroom 4 Comparison of an "Inclisiran First" Strategy with Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial Targeting Weight Loss to Personalize the Prevention of Type 2 Diabetes Once-weekly Semaglutide in Patients with Heart Failure With Preserved Ejection Fraction, (..)

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103

Cardiology Update

APRIL 9, 2024

STEP-HFpEF DM 5 ( NCT04916470 ) explored the effects of semaglutide in obesity-related HF with preserved ejection fraction (HFpEF) and type 2 diabetes. Investigators randomized 616 adult patients with HFpEF and obesity to receive either once weekly semaglutide (n=310) or placebo (n=306).

Myocardial Infarction 52

Myocardial Infarction Angina Aortic valve Coronary Artery Disease 52

NEJM Journal Watch - Cardiology

JULY 11, 2024

Both men and women derived clinical benefit from semaglutide, although women lost more weight.

Preserved Ejection Fraction 81

Preserved Ejection Fraction Heart Failure Obesity 81

DAIC

JUNE 26, 2024

Getty Images milla1cf Wed, 06/26/2024 - 18:59 June 26, 2024 — Semaglutide , a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options. The study analyzed the effects of semaglutide 2.4

Preserved Ejection Fraction 105

Preserved Ejection Fraction Obesity BMI Heart Failure 105

DAIC

MARCH 29, 2024

HFpEF is HF with preserved ejection fraction in which pressure builds up in the heart and lungs due to a stiffened left ventricle. This type of HF is largely associated with obesity and hypertension. There are two types of HF.

Preserved Ejection Fraction 111

Preserved Ejection Fraction Heart Failure Quality of Life Hospital 111